PB&B SA is a Swiss MedTech company founded in 2013 by bioengineers who teamed up with plastic surgeons & scientists to create natural & minimally invasive solutions for facial aging & body shaping.
Based on Life Sciences knowledge, PB&B developed an injection to increase adipose (fat) volume in situ using the most advanced microencapsulation & drug delivery technologies
Following over 5 years of pre-clinical studies – supported by Swiss state & federal innovation funding & support – Clinical testing will be launched in Q1-2021, for an expected market approval in 2023. Backed by international investors, PB&B has operations in the USA, China, France, the Netherlands and Switzerland.
– 3 Bioengineers EPFL (#12 QS World University Ranking)
– 15 years of business experience (combined)
Meet our team of bioengineers working internationally with doctors and scientists to develop its exciting technology and products.
Anthony Aho – CEO & Co-Founder
Lead: Business Development Strategy, Fundraising, PR & Communication.
Swiss-Canadian bioengineer & entrepreneur. Anthony Aho has a BSc in Life Sciences and a MSc in Bioengineering & Biotechnology from EPFL. He worked as scientific collaborator in clinical research at CHUV and International private school education.
Languages: English, French, Portuguese (Brazilian)
Adrenaline Lifestyle: Adventure travelling (+30 countries), Skiing, Surfing, and Downhill mountain biking, and the great outdoors.
Sergio Klinke – COO & Co-Founder
Lead: Regulatory Affairs, Clinical Trials, Finances & Accounting, Administration
Swiss-Italian bioengineer & clinical trials expert. Sergio obtained a BSc in Life Sciences, MSc in Bioengineering & Biotechnology and a MSc in Management of Technology & Entrepreneurship at EPFL. He worked 3 years in clinical trials & operations at Celgene & Medtronic, as well as 1 year at the Swiss Institute for Cancer Experimental Research (ISREC).
Languages: English, French, Italian
Lifestyle: Cooking, American car restoration, Wind surfing and Magic: The Gathering® enthousiast
Dr. Sandeep Raghunathan – (PhD)- Chief of Strategy & Science and Co-founder
Lead: Scientific operations, collaborations & strategy
Indian bioengineer & chemical engineer. Sandeep obtained a MSc in Chemical engineering and a PhD in Bioengineering in nanoparticle vaccine delivery at EPFL. In his free time, Sandeep is a free-lance geopolitical analyst, while contributing to scientific fields ranging from cognitive neuroscience to spectrography at the best labs in the world.
Languages: English, Tamil, Hindi, Bengali, French (a smattering)
Lifestyle: Macroeconomics & Human behavior research, Rock climbing, Skiing, Hiking, Whisky and Classical music.
PB&B Advisory board
Dr. Wiliam Austen
Based in Boston – the US’s Life Sciences biggest innovation hub – Dr. Austen, who is the Chief of Plastic & Reconstructive Surgery at the Massachussets General Hospital (MGH), is an authority on medical device innovation and has led the development of numerous patents and prototypes related to anti-aging, rejuvenation and scar therapy.
Dr. Austen’s strong expertise in fat transfer in plastic surgery and position at MGH and Harvard make an ideal strategic fit towards the US clinical testing phase of the project.
Dr. Grant Stevens
Dr. Stevens is the Medical director and FOunder of Marina Plastic Surgery as well as the VP and Director of ASAPS (American Society for Aesthetic Plastic Surgery). Dr. Stevens made key contributions to the success of ZELTIQ (CoolSculpting – largest market share for non-invasive fat reduction procedures).
A regular featured speaker at ASAPS and ISAPS events, Dr. Stevens is great at introducing and marketing new Aesthetic products to the plastic surgery community. Recognized as one of the best plastic surgeons in America, he was elected by his peers into the “The Guide to Top Doctors” and Castle Connolly’s “Top Doctor Guide
Dr. Pierre Quinodoz
Former president of the Swiss Society for Plastic, Reconstructive & Aesthetic Surgery (SSCPRE) and holder of the European board of Plastic Surgery, Dr. Quinodoz has completed numerous training courses in surgical techniques, notably in the United States, in Brazil and Australia. His work has received several distinctions, such as the prize from the Swiss Society for Plastic, Reconstructive and Aesthetic surgery for his doctoral thesis in 1999. He set up his private practice in Geneva in 2001 and works in some of the best surgical infrastructures in Switzerland. He is also a founding member of the Swiss Society for Aesthetic Surgery (SSME).
CEO & Co-founder of HintMD, Inc., a technology start-up based in Silicon Valley that is bringing to market an Aesthetics ExpertCommerce™ Platform for plastic surgeons, dermatologists, and patients.
Formerly VP of Asia-Pacifc at ZELTIQ Aesthetics, he executed on one of the most successful turn-around efforts within the medical aesthetics industry. At its height, ZELTIQ reached a market cap of over $1.5 Billion, before being acquired by Allergan for $2.4 billion in cash in 2017.
PB&B’s scientific journey started over a decade ago when the co-founders met in Life Sciences at EPFL. Their passion for Aesthetics & vision to create products to render plastic surgery natural & minimally invasive, brought together a diverse team of federally funded Swiss plastic surgeons & scientists from Europe’s top universities to test and optimize PB&B’s platform technology.
PB&B has won numerous national & international international innovation awards & nominations which include Venture Kick, MassChallenge, IMD Startup Competition, OneStart, RSC Emerging Technologies, >>Venture>>, and the University Hospitals of Geneva Innovation Trophy.
PB&B’s development is supported by CTI (Commission for Technology & Innovation | Swiss Government) and the local state (Canton de Vaud) economic promotion department. With this support, PB&B’s commercial network and ties have expanded to the USA, China, and Brazil.
Global Aesthetic Market & Growth
2016 Key Figures*:
– $1.65 billion in direct Sales of dermal fillers*
– +7 million filler injections
*not including China